Study to Assess the Safety, Tolerability, Pharmacokinetic of Thrv-1268

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 15, 2024

Primary Completion Date

November 1, 2024

Study Completion Date

November 1, 2024

Conditions

Atrial Fibrillation

Interventions

DRUG

THRV-1268

THRV-1268 a serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor

OTHER

Placebo

Matching placebo

Trial Locations (1)

Altasciences, Montreal

All Listed Sponsors

lead

Thryv Therapeutics, Inc.

INDUSTRY

NCT06507839 - Study to Assess the Safety, Tolerability, Pharmacokinetic of Thrv-1268 | Biotech Hunter | Biotech Hunter